Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ping Chuan Ke Li is a traditional Chinese herbal medicine formulation used primarily for the treatment of asthma. It is typically administered as granules and has been used in China for several decades. The formula consists of multiple herbal ingredients designed to relieve symptoms such as coughing and wheezing associated with asthma. Clinical studies have evaluated its effectiveness and safety in patients with mild to moderate persistent asthma, often as an adjunctive therapy alongside standard treatments like montelukast. However, available evidence suggests that after one month of treatment, Ping Chuan Ke Li does not significantly improve lung function or quality of life compared to control groups[1][2][3]. The precise mechanism of action is not fully elucidated but may involve anti-inflammatory effects and modulation of immune responses based on preclinical studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ping Chuan Ke Li.